USPTO Patent Applications - Peptides (C07K)

Anti-Hemojuvelin (HJV) Antibodies for Treating Myelofibrosis US20260098088A1

USPTO published patent application US20260098088A1 assigned to Disc Medicine, Inc. The application covers anti-hemojuvelin (HJV) antibodies and methods for treating myelofibrosis and associated conditions. Inventors include Maria Beconi, John Quisel, Brian MacDonald, Steven Robinette, Bernhard Mueller, Andreas Popp, and Jennifer M. Perez. CPC classifications include C07K 16/28 and related antibody technology classes.

CD7 Antibody Antagonists for Therapeutic Applications

USPTO published patent application US20260098089A1 titled 'CD7 Antibody Antagonists for Therapeutic Applications' filed September 8, 2025 by inventors E-Chiang Lee, Gwenoline Borhis, Cassandra Van Krinks, Lucy Hepburn, Luke Bayliss, and Miha Kosmac. The application covers Cluster of Differentiation 7 (CD7) antibody antagonists and fragments for therapeutic uses, including methods, uses, and combinations. Patent applications establish priority dates and filing status but do not yet grant enforceable intellectual property rights.

HIV/HBV Treatment Using CD8-Targeting Fusion Proteins

USPTO published patent application US20260098090A1 on April 9, 2026, disclosing fusion proteins for treating chronic viral infections including HIV and HBV. The application describes methods using CD8-targeting fusion proteins comprising antibodies specific to CD8b or CD8ab antigens combined with cytokines, chemokines, or growth factors. Inventors are Kelly Dare Moynihan, Yik Andy Yeung, and Ivana Djuretic, with filing date September 28, 2023.

Cμ4 Region for Multi-Specific Antibody Chain Pairing

USPTO published patent application US20260098094A1 assigned to DNA Twopointo, Inc. covering multi-specific antibodies with IgM Cμ4 region pairing domains for correct heavy and light chain pairing. The invention promotes correct chain combinations and disfavors incorrect pairings in bispecific antibodies. The application was filed November 21, 2025.

Ovarian Cancer Diagnostic Marker, Urteste S.A

Ovarian Cancer Diagnostic Marker, Urteste S.A

Peptide Compositions Targeting β-Catenin for Treatment of Endometriosis

USPTO published patent application US20260098059A1 for peptide compositions targeting β-catenin for treatment of endometriosis. The application covers peptides that bind β-catenin and prevent nuclear translocation, modulating the canonical Wnt pathway. Filed October 10, 2025 under Application No. 19355926. Patent rights are not yet granted; applicants seeking to develop similar therapies should review the published claims for freedom-to-operate considerations.

Macrocyclic CFTR Modulators for Cystic Fibrosis

USPTO published patent application US20260098060A1 for macrocyclic CFTR modulators for treating cystic fibrosis. The application covers compounds of Formula (I), their preparation, pharmaceutical salts, and uses as CFTR modulators or in combination with CFTR potentiators/correctors. Inventors include Martin Bolli, Christine Brotschi, John Gatfield, and others. The application was filed on September 14, 2023.

EphA2-binding Peptide and Composition Patent Application

The USPTO published patent application US20260098061A1 for an EphA2-binding peptide and composition comprising such peptides. The application, filed on September 28, 2023, lists 13 inventors including Takanori Aoki and others. The patent covers peptides that bind to the Eph receptor A2 (EphA2) and compositions containing such peptides, with CPC classifications C07K 7/64 and A61K 47/64.

Lipid Particles Comprising Variant Paramyxovirus Attachment Glycoproteins

USPTO published patent application US20260098062A1 assigned to Sana Biotechnology, Inc. covering lipid particles comprising variant Paramyxovirus attachment glycoproteins with reduced glycosylation and methods for their production and use. The application (originally filed September 21, 2023) covers viral-based particles with modified G/H proteins and their therapeutic applications.

HPV Vaccine Peptide Constructs with Ligand-Inducible Gene Switch Systems

The USPTO published patent application US20260098063A1 titled 'Human Papillomavirus Vaccines and Uses of the Same.' The application covers engineered HPV molecular vaccine constructs incorporating ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as cytokines, in host cells. The application was filed on July 7, 2025, by inventors including Douglas E. Brough and Cheryl G. Bolinger. Patent applications are published for informational purposes and do not grant enforceable rights until issued as a patent after examination.

LANMODULIN ORTHOLOGS WITH IMPROVED RARE EARTH SEPARATION PERFORMANCE

USPTO published patent application US20260098064A1 for lanmodulin orthologs (proteins) designed to bind rare earth metals with enhanced REE/REE selectivity. The application covers proteins with four EF hand motifs, methods of using the proteins, and devices/kits containing them. The invention has applications in rare earth element separation and processing.

Advagene Biopharma Patent for Asthma Treatment Using Detoxified E. coli Labile Toxin

USPTO published patent application US20260098065A1 assigned to Advagene Biopharma Co., Ltd. covering methods for treating eosinophil-driven inflammation including severe asthma using a composition for mucosal administration comprising detoxified Escherichia coli labile toxin.

Polygon Therapeutics Anti-CD8 Antibodies for Immunotherapy

Polygon Therapeutics Anti-CD8 Antibodies for Immunotherapy

Anti-sIL7R Antibody Therapy for Treating Autoimmune Diseases

The USPTO published patent application US20260098099A1 assigned to the Board of Regents of the University of Texas System, covering methods and compositions for anti-soluble interleukin-7 receptor (sIL7R) antibodies for treating autoimmune diseases including multiple sclerosis, lupus nephritis, type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. The application was filed on August 10, 2025.

IL-4R and TSLP Inhibitors, Inflammatory Treatment Patent Application

USPTO published patent application US20260098100A1 covering antigen binding moieties that inhibit IL-4R and TSLP pathways for inflammatory disease treatment. The application names Miguel A. Sanjuan, Sheila Gujrathi, and Ryan P. Sullivan as inventors and was filed November 10, 2025. The disclosed invention blocks IL4-IL-4R and TSLP-TSLPR interactions, targeting the same pathways addressed by approved drugs Dupilumab and Tezepelumab.

Anti-IL-36R Monoclonal Antibody and Use Thereof for Inflammatory Disease Treatment

USPTO published patent application US20260098101A1 from QYUNS THERAPEUTICS CO., LTD. covering an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody for inflammatory disease treatment. The application was filed on December 4, 2025. The antibody comprises six complementarity determining regions with amino acid sequences specified in the filing, and the applicant claims superior neutralizing activity compared to Spesolimab at the cellular level.

Anti-SIRPalpha Antibody for Tumor Treatment

USPTO published patent application US20260098102A1 by National University Corporation Kobe University on April 9, 2026. The application discloses an anti-SIRPα monoclonal antibody that binds human SIRPα to inhibit the SIRPα/CD47 interaction for use as an anti-tumor agent. The invention is classified under C07K 16/28 and related peptide technology categories.

Compositions and Methods for Identification of VHH Antibodies That Bind a Target Antigen

The USPTO published patent application US20260098255A1 for Broad Institute's VHH antibody identification methods. The application covers compositions and methods for identifying VHH antibodies that bind target antigens. The application (No. 19415305) was filed December 10, 2025, and published April 9, 2026.

CRISPR Methods for Treating Microbial Infections - SNIPR Biome

SNIPR Biome ApS filed USPTO patent application US20260098260A1 covering CRISPR-based methods for treating microbial infections including sepsis, septicemia, SIRS, and septic shock. The application also covers controlling microbiologically influenced corrosion and biofouling in industrial or domestic systems using CRISPR technology. Inventors include Morten Sommer, Virginia Martinez, Eric van der Helm, Jakob Krause Haaber, Ana de Santiago Torio, Christian Grøndahl, and Jasper Clube.

Composition Improves Salt Tolerance in Plants

Composition Improves Salt Tolerance in Plants

Surface-Modified Viral Particles and Modular Viral Particles Patent Application

USPTO published patent application US20260098280A1 for surface-modified viral particles and modular viral particles (anellovectors and anelloVLPs) filed December 8, 2025. The application names five inventors including Simon Delagrave, Kurt Adam Swanson, and Noah Robert Cohen. CPC classifications include C12N 15/86 and C07K 14/005.

NAVROGEN Fc-Engineered Monoclonal Antibodies Targeting ICAM-1/CD54 for Cancer Treatment

USPTO published patent application US20260098858A1 for NAVROGEN, INC. covering Fc-engineered monoclonal antibodies with CH3 region modifications designed to reduce ICAM-1/CD54 binding, improving immune-effector activity and antibody drug conjugate killing for cancer and inflammatory disease treatment.

TACI Antibody and Use Thereof for Detecting Free Drug Levels

The USPTO published patent application US20260098866A1 covering a human TACI (B lymphocyte stimulator receptor) antibody with high specificity and affinity, along with methods for detecting free TACI or TACI-Fc fusion protein drug levels in patients. The invention enables monitoring of drug absorption and therapeutic efficacy in patients with autoimmune diseases.

Methods for Rule-based Genome Design

USPTO published patent application US20260100251A1 for computer-implemented methods of rule-based genome design. The application covers systems receiving known genome data and allele lists, generating alternative gene sequences, and scoring each sequence using a weighted combination of multiple rules, constraints, or parameters. Inventors include George M. Church and Nili Ostrov.

Washington University Patents UTI Treatment Using Hemolysin Inhibitor

The USPTO published Washington University's patent application (US20260098073A1) for compositions and methods treating urinary tract infection and sepsis using alpha-hemolysin (HlyA) inhibiting agents. The technology includes soluble LDLR-Fc fusion proteins, clathrin-mediated endocytosis inhibitors, and anti-LDLR antibodies targeting E. coli hemolysin. This grants Washington University exclusive IP rights over these therapeutic compositions.

CAR TCR Cell Therapy Patent Improves Cytokine Signaling

USPTO published patent application US20260098074A1 by inventors Ruth E. Winter and Saikat Banerjee for CAR and/or TCR cell therapy improving cytokine signaling. The patent covers methods for enhancing immune cell function through improved cytokine signaling pathways in cell therapy applications. The application was filed on 2025-07-15.

Modified LGICs with Altered Ligand Binding, Ion Pore Domains

USPTO published patent application US20260098076A1 for modified ligand-gated ion channels (LGICs) with altered ligand binding domains and ion pore domains. The invention covers exogenous LGIC ligands, methods for modulating ion transport and cell excitability in mammals, and methods for treating channelopathies. The application was filed on February 24, 2025.

METHOD FOR TREATING MEMBRANOUS NEPHROPATHY WITH TACI-FC FUSION PROTEIN

USPTO published patent application US20260098077A1 for a method of treating membranous nephropathy using TACI-Fc fusion protein. The application, filed September 28, 2023, discloses dosage schemes, administration intervals, and clinical efficacy data showing good safety profiles in patients.

Methods for Constructing Conjugates Using Ortho-Phthalaldehyde

USPTO published Patent Application US20260098054A1 disclosing methods for constructing conjugates using ortho-phthalaldehyde. The method involves reacting an amine-containing component with a thiol-containing component in comparable mole ratios to generate a conjugate bearing a substituted or unsubstituted 1-thio-isoindole structure. Inventors are Xuechen LI and Hey Pui CHEUNG. The application was filed on August 22, 2023.

Macrocycle and Hydrophobic Particle Method for Removing Polymers from Protein Solutions

USPTO published patent application US20260098055A1 for a method of removing free polymers from solutions containing hydrophobic proteins using macrocycles and/or hydrophobic particles. The application (CPC C07K 1/145) was filed September 7, 2023, with inventors including Barbara Maertens and colleagues. This pre-grant publication does not confer any enforceable rights.

P80 Protein Treatment Method Using Pharmaceutical Composition Comprising Neurotoxin Associated Polypeptide

The USPTO published patent application US20260098066A1 assigned to Prime Bio, Inc., covering a method of treating disorders using a pharmaceutical composition comprising a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E. The p80 acts as a tight junction modulator to enhance intestinal epithelium permeability, facilitating drug delivery and increasing bioavailability of therapeutic agents including drugs, small molecules, proteins, and biomolecules.

DWORF Peptide SERCA Pump Activator Heart Failure Treatment

The USPTO published patent application US20260098067A1 by researchers at the University of Texas System covering the DWORF (Dwarf Open Reading Frame) peptide, a native SERCA pump activator for treating heart failure and disorders characterized by cytosolic calcium overload. The application claims compositions and methods using this positively inotropic and lusitropic therapeutic agent.

GC-Globulin Patent Claims Diabetes Treatment

USPTO published patent application US20260098068A1 for GC-globulin or variants for treating diabetes, filed September 22, 2023. The application names David Hodson, Katrina Viloria, and Martin Hewison as inventors and covers compositions and methods for diabetes treatment using the vitamin D-binding protein.

Recombinant Lubricin Patent - Schmidt and Jay Inventors

USPTO published patent application US20260098069A1 for recombinant isoforms of human-like lubricin (PRG4 glycoprotein) invented by Tannin A. Schmidt and Gregory D. Jay. The patent covers new lubricin isoforms with novel glycosylation patterns and methods for commercial-scale manufacturing using recombinant production methods.

SMAGP Fusion Molecules Modulate Leukocyte Activity

USPTO published patent application US20260098070A1 disclosing fusion molecules comprising a SMAGP extracellular domain designed to modulate leukocyte activity. The application covers polynucleotides, vectors, and host cells encoding these molecules along with methods of making and using them. Inventors include Loise M. Francisco-Anderson, Sandeep Kumar, Sarah Elizabeth Carden, Christophe Quéva, and Nenad Grmusa, with filing date July 7, 2025.

GLP-1 Analog for Treatment of GLP-1 Related Diseases

USPTO published patent application US20260098071A1 for a novel human GLP-1 analog invented by Tao Sun. The disclosed analog demonstrates improved efficacy compared to natural GLP-1 sequence in treating obesity, type 2 diabetes mellitus, fatty liver, and mood disorders including anxiety and depression. The application was filed on December 4, 2024, under application number 18968327.

Methods of Stimulating Appetite Using Non-Naturally Occurring Melanocortin Receptor Antagonist Analogs

The USPTO published patent application US20260098072A1 by inventor Russell Potterfield on April 9, 2026, covering methods of increasing body weight and stimulating appetite using non-naturally occurring melanocortin receptor antagonist analogs. The application, filed April 18, 2025, relates to pharmaceutical compositions administered via parenteral routes such as subcutaneous injection for subjects requiring appetite stimulation and weight gain.

Ultra-Long-Acting Platform Comprising Fc-Advanced Fatty Acid Chain Extending Drug Half-Life

The USPTO published patent application US20260097125A1 for an ultra-long-acting drug delivery platform combining immunoglobulin Fc with a modified C14-24 fatty acid chain. The conjugated molecule structure 'active molecule-Fc-Cn' is designed to extend the half-life of therapeutic active molecules. The application was filed on September 22, 2023, with eight inventors including Faming Zhang, Yimin Hu, and colleagues.

Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion

Recombinant Fusion Polypeptides Enable Bacteroides Cargo Secretion

Universal Peptide/MHC Complexes with Engineered Disulfide

The USPTO published patent application US20260097105A1 by Nikolaos SGOURAKIS for synthetic major histocompatibility complex (MHC) molecules featuring engineered disulfide linkages connecting heavy and light chains. The invention covers systems, formulations, and methods for generating universal peptide/MHC complexes using structure-guided modeling and design. Application No. 19114130 was filed September 28, 2023, with CPC classifications including A61K 39/001188, A61K 39/385, C07K 14/4748, and C07K 14/70539.

Flavivirus Vaccine Polynucleotides Inducing Protective CD8+ T Cell Immunity

USPTO published patent application US20260097108A1 by inventors Charneau et al. disclosing recombinant polynucleotides encoding non-structural antigens from Dengue virus (DENV), Zika virus (ZIKV), and Yellow Fever virus (YFV) designed to elicit protective CD8+ T-cell immune responses. The application covers polyepitope fusion polypeptides and lentiviral vectors for flavivirus vaccine development.

ActRIIB ectodomain variants treating metabolic disorders and fibrosis

USPTO published patent application US20260092096A1 for Activin receptor type IIB (ActRIIB) ectodomain variants fused to Fc domain for treating metabolic disorders, diabetes, obesity, fibrosis, and muscle atrophy. The application (No. 19206991) was filed May 13, 2025, by inventors Maureen D. O'Connor-McCourt et al.

Adeno-Associated Virus Producer Cell Lines Patent Application

The USPTO published patent application US20260092284A1 for Adeno-Associated Virus (AAV) producer cell lines and methods of producing AAVs. The application, filed August 15, 2025, covers nucleic acids encoding helper genes and AAV genes under inducible promoter control, as well as mammalian cell lines for AAV production. Inventors include Bingnan Gu, Gang Li, and Caitlin Tripp.

Heparan-N-sulfatase purification via multi-mode chromatography

The USPTO published patent application US20260092264A1 on April 2, 2026, disclosing a novel method for purifying heparan-N-sulfatase using multi-mode chromatography combined with caprylate precipitation. Invented by six researchers, the method removes host cell proteins and improves purity and stability of the enzyme for potential pharmaceutical applications.

Netrin-1 peptide amphiphiles treat central nervous system injury

USPTO published patent application US20260092252A1 for Netrin-1 mimetic peptide amphiphiles for treating central nervous system injury. The application covers peptide compositions and methods of use. Inventors include Samuel Isaac Stupp, Cara Stephanie Smith, and Zaida Alvarez Pinto.

Princeton University patent for cloacaenodin, antimicrobial lasso peptide

Princeton University patent for cloacaenodin, antimicrobial lasso peptide

Method of Making a Pharmaceutical Composition Comprising a p80 Protein

USPTO published patent application US20260092087A1 by Prime Bio, Inc. covering a method for producing recombinant p80 polypeptide using E. coli culture with L-Arabinose induction. The p80 protein functions as a tight junction modulator to enhance intestinal permeability for therapeutic agents. The application (No. 19352451) was filed October 7, 2025.

Variant Anti-Viral Polypeptides

The USPTO published patent application US20260092088A1 for variant lectin anti-viral polypeptides filed by inventors Cristina BONGIORNI, Mai DU, David A. ESTELL, Keith FROGUE, Amy Deming LIU, and Darshana KADEKAR. The application covers engineered anti-viral lectin compositions for treating and preventing viral diseases in animals, with a filing date of September 19, 2023.

Recombinant Vaccine Against Helminths in Pichia pastoris

USPTO published patent application US20260092089A1 by Fundação Oswaldo Cruz disclosing recombinant production of Sm14 Schistosoma mansoni vaccine antigen using genetically engineered Pichia pastoris strains with methanol-inducible (AOX1) and constitutive (GAP) promoters. The application covers synthetic gene construction, fermentation processes, and protein purification methods scalable for industrial vaccine manufacturing.

NGF Mutein Production Process Patent Application

Chiesi Farmaceutici SpA filed USPTO patent application US20260092090A1 on April 2, 2026, for a process producing nerve growth factor (NGF) and muteins at high purity from recombinant sources. The muteins may exhibit improved detectability and reduced nociceptive activity compared to wildtype human NGF. Application No. 19265384 was filed July 10, 2025.